Open AccessAssociation Between the COMT Val158Met Polymorphism and Antipsychotic Efficacy in Schizophrenia: An Updated Meta-Analysis
Author(s) -
Jianchao Ma,
Mingzhe Zhao,
Wei Zhou,
Mo Li,
Hui Cong,
Lu Shen,
Ting Wang,
Hao Wu,
Na Zhang,
Zhiruo Zhang,
Lin He,
Shengying Qin
Publication year - 2021
Publication title -
current neuropharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.955
H-Index - 73
eISSN - 1875-6190
pISSN - 1570-159X
DOI - 10.2174/1570159x18666201023154049
Subject(s) - rs4680 , catechol o methyl transferase , antipsychotic , meta analysis , medicine , schizophrenia (object oriented programming) , publication bias , randomized controlled trial , typical antipsychotic , oncology , psychiatry , psychology , genotype , atypical antipsychotic , genetics , biology , gene
Catechol-O-methyltransferase (COMT) contributes to the control of synaptic dopamine (DA) transmission by catalyzing DA degradation in the presynaptic space. The COMT Val158Met polymorphism (rs4680) substantially alters enzymatic activity and consequently synaptic DA concentration in the prefrontal cortex and hippocampus. The COMT genotype could, therefore, exert a major influence on antipsychotic treatment response as many of these agents also target dopaminergic transmission.